Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis

Nature Chemical Biology volume 10, pages 977–983 (2014)Cite this article

Subjects

Abstract

Aberrant signaling through the Axl receptor tyrosine kinase has been associated with a myriad of human diseases, most notably metastatic cancer, identifying Axl and its ligand Gas6 as important therapeutic targets. Using rational and combinatorial approaches, we engineered an Axl 'decoy receptor' that binds Gas6 with high affinity and inhibits its function, offering an alternative approach from drug discovery efforts that directly target Axl. Four mutations within this high-affinity Axl variant caused structural alterations in side chains across the Gas6-Axl binding interface, stabilizing a conformational change on Gas6. When reformatted as an Fc fusion, the engineered decoy receptor bound Gas6 with femtomolar affinity, an 80-fold improvement compared to binding of the wild-type Axl receptor, allowing effective sequestration of Gas6 and specific abrogation of Axl signaling. Moreover, increased Gas6 binding affinity was critical and correlative with the ability of decoy receptors to potently inhibit metastasis and disease progression in vivo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Engineering and characterization of receptor-based Axl antagonists.
Figure 2: Structural basis for high-affinity binding.
Figure 3: Design and characterization of Axl Fc fusion proteins.
Figure 4: MYD1 Fc inhibits Axl activation and downstream signaling in skov3.ip cells.
Figure 5: Sequestration of Gas6 by MYD1 Fc inhibits metastasis.

Similar content being viewed by others

Accession codes

Primary accessions

Protein Data Bank

Referenced accessions

Protein Data Bank

References

  1. Lemke, G. & Rothlin, C.V. Immunobiology of the TAM receptors. Nat. Rev. Immunol. 8, 327–336 (2008).

    Article  CAS  Google Scholar 

  2. Li, Y. et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28, 3442–3455 (2009).

    Article  CAS  Google Scholar 

  3. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852–860 (2012).

    Article  CAS  Google Scholar 

  4. Hong, J., Peng, D., Chen, Z., Sehdev, V. & Belkhiri, A. ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res. 73, 331–340 (2013).

    Article  CAS  Google Scholar 

  5. Byers, L.A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279–290 (2013).

    Article  CAS  Google Scholar 

  6. Vajkoczy, P. et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc. Natl. Acad. Sci. USA 103, 5799–5804 (2006).

    Article  CAS  Google Scholar 

  7. Linger, R.M., Keating, A.K., Earp, H.S. & Graham, D.K. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35–83 (2008).

    Article  CAS  Google Scholar 

  8. Gustafsson, A. et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin. Cancer Res. 15, 4742–4749 (2009).

    Article  CAS  Google Scholar 

  9. Chen, P.X., Li, Q.Y. & Yang, Z. Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann. Diagn. Pathol. 17, 425–429 (2013).

    Article  Google Scholar 

  10. Rankin, E.B. et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 70, 7570–7579 (2010).

    Article  CAS  Google Scholar 

  11. Holland, S.J. et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70, 1544–1554 (2010).

    Article  CAS  Google Scholar 

  12. Yan, S.B. et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest. New Drugs 31, 833–844 (2013).

    Article  CAS  Google Scholar 

  13. Ye, X. et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254–5264 (2010).

    Article  CAS  Google Scholar 

  14. Leconet, W. et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene 10.1038/onc.2013.487 (2013).

  15. Cerchia, L. et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol. Ther. 20, 2291–2303 (2012).

    Article  CAS  Google Scholar 

  16. Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508–512 (2014).

    Article  CAS  Google Scholar 

  17. Fabian, M.A. et al. A small molecule–kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329–336 (2005).

    Article  CAS  Google Scholar 

  18. Fisher, P.W. et al. A novel site contributing to growth-arrest–specific gene 6 binding to its receptors as revealed by a human monoclonal antibody. Biochem. J. 387, 727–735 (2005).

    Article  CAS  Google Scholar 

  19. Varnum, B.C. et al. Axl receptor tyrosine kinase stimulated by the vitamin-K–dependent protein encoded by growth-arrest-specific gene-6. Nature 373, 623–626 (1995).

    Article  CAS  Google Scholar 

  20. Meyer, A.S., Miller, M.A., Gertler, F.B. & Lauffenburger, D.A. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci. Signal. 6, ra66 (2013).

    PubMed  PubMed Central  Google Scholar 

  21. Kariolis, M.S., Kapur, S. & Cochran, J.R. Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics. Curr. Opin. Biotechnol. 24, 1072–1077 (2013).

    Article  CAS  Google Scholar 

  22. Economides, A.N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9, 47–52 (2003).

    Article  CAS  Google Scholar 

  23. Peppel, K., Crawford, D. & Beutler, B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174, 1483–1489 (1991).

    Article  CAS  Google Scholar 

  24. Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393–11398 (2002).

    Article  CAS  Google Scholar 

  25. Sasaki, T. et al. Structural basis for Gas6-Axl signalling. EMBO J. 25, 80–87 (2006).

    Article  CAS  Google Scholar 

  26. Darling, R.J. & Brault, P.A. Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev. Technol. 2, 647–657 (2004).

    Article  CAS  Google Scholar 

  27. Hafizi, S. & Dahlback, B. Gas6 and protein S. Vitamin K–dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 273, 5231–5244 (2006).

    Article  CAS  Google Scholar 

  28. Manfioletti, G., Brancolini, C., Avanzi, G. & Schneider, C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K–dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol. Cell. Biol. 13, 4976–4985 (1993).

    Article  CAS  Google Scholar 

  29. Sasaki, T. et al. Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6—receptor tyrosine kinase activation by laminin G–like domains. J. Biol. Chem. 277, 44164–44170 (2002).

    Article  CAS  Google Scholar 

  30. Chakrabartty, A., Doig, A.J. & Baldwin, R.L. Helix capping propensities in peptides parallel those in proteins. Proc. Natl. Acad. Sci. USA 90, 11332–11336 (1993).

    Article  CAS  Google Scholar 

  31. Levin, A.M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484, 529–533 (2012).

    Article  CAS  Google Scholar 

  32. Marshall, S.A., Lazar, G.A., Chirino, A.J. & Desjarlais, J.R. Rational design and engineering of therapeutic proteins. Drug Discov. Today 8, 212–221 (2003).

    Article  CAS  Google Scholar 

  33. Gjerdrum, C. et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. USA 107, 1124–1129 (2010).

    Article  CAS  Google Scholar 

  34. Aslakson, C.J. & Miller, F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405 (1992).

    CAS  PubMed  Google Scholar 

  35. Wan, L., Pantel, K. & Kang, Y. Tumor metastasis: moving new biological insights into the clinic. Nat. Med. 19, 1450–1464 (2013).

    Article  CAS  Google Scholar 

  36. Lu, Q. et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723–728 (1999).

    Article  CAS  Google Scholar 

  37. Angelillo-Scherrer, A. et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med. 7, 215–221 (2001).

    Article  CAS  Google Scholar 

  38. Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508–512 (2014).

    Article  CAS  Google Scholar 

  39. Boder, E.T. & Wittrup, K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553–557 (1997).

    Article  CAS  Google Scholar 

  40. Chao, G. et al. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1, 755–768 (2006).

    Article  CAS  Google Scholar 

  41. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).

    Article  CAS  Google Scholar 

  42. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22–25 (2010).

    Article  CAS  Google Scholar 

  43. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).

    Article  Google Scholar 

  44. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255 (1997).

    Article  CAS  Google Scholar 

  45. The PyMOL Molecular Graphics System. Version 1.3r1, Schrödinger, LLC (2010).

  46. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).

    Article  CAS  Google Scholar 

  47. Yuan, Z., Zhao, J. & Wang, Z.X. Flexibility analysis of enzyme active sites by crystallographic temperature factors. Protein Eng. 16, 109–114 (2003).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank E. Hohenester (Imperial College London) for his generous gift of the Gas6 plasmid and helpful discussions regarding protein production, L.L. Zheng for technical assistance with protein production and purification and the Stanford FACS Core Facility for assistance with the flow cytometric sorting. All in vivo and ex vivo imaging was conducted in the Stanford Small Animal Imaging Facility. Portions of this research were performed at the Stanford Synchrotron Radiation Laboratory, a national user facility operated by Stanford University on behalf of the US Department of Energy Office of Basic Energy Sciences. This work was supported by the Wallace H. Coulter Translational Research Grant Program (J.R.C. and A.J.G.), the Stanford Chemistry, Engineering & Medicine for Human Health (ChEM-H) Institute (J.R.C. and I.I.M.), Stanford Bio-X and ARCS Graduate Fellowships (M.S.K.), US National Institutes of Health (NIH) grants CA-088480 and CA-67166 (A.J.G. and Y.R.M.), NIH National Institute of General Medical Sciences Training Grant T32 GM008412 and the Siebel Graduate Fellowship (D.S.J.).

Author information

Authors and Affiliations

  1. Department of Bioengineering, Stanford University, Stanford, California, USA

    Mihalis S Kariolis, Douglas S Jones II, Shiven Kapur & Jennifer R Cochran

  2. Department of Radiation Oncology, Stanford University School of Medicine, Stanford University, Stanford, California, USA

    Yu Rebecca Miao & Amato J Giaccia

  3. Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, Menlo Park, California, USA

    Irimpan I Mathews

  4. Department of Chemical Engineering, Stanford University, Stanford, California, USA

    Jennifer R Cochran

Authors
  1. Mihalis S Kariolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Rebecca Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas S Jones II
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shiven Kapur
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Irimpan I Mathews
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amato J Giaccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jennifer R Cochran
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.S.K., Y.R.M., D.S.J., S.K., I.I.M., A.J.G. and J.R.C. designed the research; M.S.K. and D.S.J. performed protein engineering and characterization; M.S.K., S.K. and I.I.M. did the crystallography; M.S.K. and Y.R.M. conducted the in vivo experiments; all of the authors analyzed the data; and M.S.K. prepared the manuscript with input from all co-authors.

Corresponding authors

Correspondence to Amato J Giaccia or Jennifer R Cochran.

Ethics declarations

Competing interests

Stanford University holds patent number US8618254 B2, 'Biologic inhibitors for therapeutic targeting the receptor tyrosine kinase AXL', which is related to the work described in this paper, with M.S.K., Y.R.M., D.S.J., A.J.G. and J.R.C. named as inventors. A.J.G. is a founder of Ruga, a company that discovers and develops targeted therapeutics in oncology that has licensed this patent.

Supplementary information

Supplementary Text and Figures

Supplementary Results, Supplementary Figures 1–14 and Supplementary Tables 1–7. (PDF 6640 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kariolis, M., Miao, Y., Jones, D. et al. An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat Chem Biol 10, 977–983 (2014). https://doi.org/10.1038/nchembio.1636

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio.1636

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer